| Application no. and date | 21794474.3 (espacenet) (Federated) (European Patent Register), 20211007 | | Patent/reg. no. and date | DK/EP 4225297, 20241023 | | Publication date | 20230816 | | Priority no. and date | US 202063089195 P, 20201008 | | EP pub. no. and date |
EP 4225297 20230816 | | Effective date | | | Applicant/owner | Astrazeneca AB, 151 85 Södertälje, SE | | Applicant ref. no. | 1719535 | | Inventor | LEO, Elisabetta,
Cambridge Cambridgeshire CB2 0AA, GB | | Representative | RWS Group, RWS Compass House
Vanwall Business Park, Vanwall Road
Maidenhead, Berkshire
SL6 4UB, GB | | Opponent | | | IPC Class | A61K 31/282 (2006.01) , A61K 31/496 (2006.01) , A61K 31/555 (2006.01) , A61K 33/243 (2019.01) , A61K 45/06 (2006.01) , A61P 35/00 (2006.01) | | Title | KOMBINATIONSBEHANDLING TIL BEHANDLING AF CANCER | | Int. application no. | EP2021077703 | | Int. publication no. | WO2022074124 | | Related patent (certificate) | | | Status | DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
